dpp 4 inhibitors vs glp 1 agonist Mechanism of action for GIP, GLP-1 analogues and DPP4 in Use of DPP-4 inhibitors and
Description
(Tell me in the comments #ObesityMedicine #GLP1 #WeightManagement #FDAApproval #ClinicalPharmacy #MedicationAccess #PublicHealth #HealthEquity #ThePublicHealthPharmacist To view or add a comment, sign in The FDA has granted expedited approval to Eli Lilly's new weight-loss pill, orforglipron (Foundayo), marking it as the second daily oral GLP-1 medication for obesity
Summary Table to Keep Track of Indications for GLP-GIP RAs We are excited to share this summary sheet of all the current indications for the incretin class of medication over the past ten years
R., Li, Q., Best, J
Ma et al., 2020)
